PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107

被引：0

作者：

Freeman, Mason W. ^{[1
]}

Bond, Mary ^{[2
]}

Murphy, Brian ^{[2
]}

Hui, James ^{[1
]}

Isaacson, Jonathan ^{[2
]}

机构：

[1] CinCor Pharma Inc, Boston, MA USA

[2] CinRx Pharma LLC, Cincinnati, OH USA

来源：

JOURNAL OF HYPERTENSION | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

S-16-4

引用

页码：E42 / E43

页数：2

共 50 条

[21] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Lu, Peng
Fleischmann, Roy
Curtis, Craig
Ignatenko, Stanislav
Desai, Monali
Wong, Shekman L.
Grebe, Kristie M.
Zeng, Jiewei
Medema, Jeroen
Stolzenbach, James
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[22] Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults
Ramos, Kimberly A.
James, Ian E.
Skobieranda, Franck
Soergel, David G.
Ruff, Dennis
Fossler, Michael J.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (01): : 51 - 62
[23] Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults
Landry, Ishani
Nakai, Kenya
Ferry, Jim
Aluri, Jagadeesh
Hall, Nancy
Lalovic, Bojan
Moline, Margaret L.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (02): : 153 - 165
[24] Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study
Cornpropst, M.
Collis, P.
Collier, J.
Babu, Y. S.
Wilson, R.
Zhang, J.
Fang, L.
Zong, J.
Sheridan, W. P.
ALLERGY, 2016, 71 (12) : 1676 - 1683
[25] A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
Max Tsai
Lambros Chrones
Jinhui Xie
Hakop Gevorkyan
Thomas A. Macek
Psychopharmacology, 2016, 233 : 3787 - 3795
[26] A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
Tsai, Max
Chrones, Lambros
Xie, Jinhui
Gevorkyan, Hakop
Macek, Thomas A.
PSYCHOPHARMACOLOGY, 2016, 233 (21-22) : 3787 - 3795
[27] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of macitentan, an Endothelin Receptor Antagonist, in an Ascending Multiple-Dose Study in Healthy Subjects
Sidharta, Patricia N.
van Giersbergen, Paul L. M.
Dingemanse, Jasper
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (11): : 1131 - 1138
[28] Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study
Kubitza, Dagmar
Heckmann, Michael
Distler, Jana
Koechel, Annemone
Schwers, Stephan
Kanefendt, Friederike
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3447 - 3462
[29] PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF BI 11634, A NOVEL DIRECT ORAL FACTOR XA INHIBITOR, IN A SINGLE ASCENDING DOSE STUDY
Huang, Fenglei
Formella, Stephan
Schepers, Cornelia
Rubano, Vanessa
MacGregor, Thomas R.
Breithaupt-Groegler, Kerstin
Smith, John
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1061 - 1061
[30] Safety, pharmacokinetics and pharmacodynamics of PF-05280602 (recombinant FVIIA variant): preliminary results from a single ascending dose phase I study in hemophilia A and B subjects
Gruppo, R.
Malan, D.
Kapocsi, J.
Hay, C.
Boggio, L.
Chowdary, P.
Tagariello, G.
von Drygalski, A.
Hua, F.
Scaramozza, M.
Shi, H.
Arkin, S.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 848 - 848

← 1 2 3 4 5 →